FDA approves new epoetin product: Roche unsure when it can market in United States.
Thompson
Cheryl A
CA
D000740:Anemia / Q000188:drug therapy / Q000209:etiology; D017277:Drug Approval; D004338:Drug Combinations; D004345:Drug Industry / Q000331:legislation & jurisprudence; D004921:Erythropoietin / Q000600:supply & distribution / Q000627:therapeutic use; D006397:Hematinics / Q000600:supply & distribution / Q000627:therapeutic use; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000188:drug therapy; D040541:Marketing / Q000331:legislation & jurisprudence*; D011092:Polyethylene Glycols / Q000600:supply & distribution / Q000627:therapeutic use; D011994:Recombinant Proteins; D014481:United States; D014486:United States Food and Drug Administration
D004338:Drug Combinations; D006397:Hematinics; D011994:Recombinant Proteins; C103998:epoetin beta; D004921:Erythropoietin; D011092:Polyethylene Glycols; C028210:monomethoxypolyethylene glycol